IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Nov 14, 2023 · 10-Q · 45 days after period end · 0000950170-23-063716
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | -$5.35M | -$7.92M | -$21.71M | -$21.51M |
| EPS Diluted | -$0.15 | -$0.22 | -$0.73 | -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end
